CoChat

Patients’ perspective on current treatments and demand for novel treatments in vitiligo

Open access
Narayan, V.S., Uitentuis, S.E., Luiten, R.M., Bekkenk, M.W., Wolkerstorfer, A. · 2021 · Journal of the European Academy of Dermatology and Venereology
Cited by 49

The DOI matches its Crossref record.

Abstract

Background: The treatment of non‐segmental vitiligo (NSV) remains a challenge. Current treatments often achieve suboptimal clinical results. To improve these treatment results, several new therapies are being developed and investigated. There is, however, little evidence on the actual need for novel therapies. Objective: To assess patients’ perspective on current and novel therapies for vitiligo. Methods: A prospective questionnaire study was conducted in a large cohort of vitiligo patients that consecutively visited the outpatient clinic of the Amsterdam University Medical Centre between April 2017 and January 2019. Patients were requested to fill in a digital questionnaire on patient characteristics, disease burden, quality of life, efficacy and satisfaction of current treatments and aspects regarding new treatments. Results: A total of 325 vitiligo patients completed the questionnaire (60% response rate). Of the respondents, 94% believed that new and improved treatments are needed and 86% would be willing to participate in clinical trials investigating a new therapy. Sixty‐nine per cent would agree on taking weekly injections if it led to effective treatment results. Of the patients that had received therapy before, 49% reported that the current treatments were not effective and 50% was not satisfied with the current treatments. Sixty‐seven per cent of the patients experienced facial lesions as an extreme burden, whereas this was, 25%, 12% and 10% for lesions on the hands, trunk and feet, respectively. The emotional burden score was significantly higher in dark skin types compared with light skin types (respectively, 8 vs 5, U P < 0.05). Conclusion: There is a substantial need for new vitiligo therapies. A considerable number of patients in our study are dissatisfied with current treatments and are emotionally burdened by the disease. Moreover, the vast majority demands novel treatments and is willing to participate in clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jdv.16927

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 20

  1. 10.1016/j.jaad.2010.11.061 · DOI · Paper page
  2. 10.1016/j.jaad.2009.03.022 · DOI · Paper page
  3. 10.1016/j.clindermatol.2017.01.001 · DOI
  4. 10.1111/bjd.15933 · DOI · Paper page
  5. 10.1016/j.jaad.2016.11.010 · DOI · Paper page
  6. 10.1016/j.jaci.2017.07.011 · DOI
  7. 10.1177/1203475419833609 · DOI
  8. Bergqvist C, 2020, Vitiligo: a review, Dermatology, 1
  9. 10.1111/j.1365-2133.2009.09091.x · DOI · Paper page
  10. 10.1038/JID.2015.398 · DOI
  11. 10.1016/j.jaad.2019.02.008 · DOI
  12. 10.1186/1477-7525-1-58 · DOI
  13. 10.1590/S0365-05962009000100006 · DOI
  14. 10.1046/j.1468-3083.2001.00336.x · DOI · Paper page
  15. 10.1001/jamadermatol.2016.4670 · DOI
  16. 10.1016/j.jaad.2014.12.012 · doi:10.1016/j.jaad.2014.12.012
  17. 10.1111/j.1365-2133.2012.11056.x · DOI · Paper page
  18. 10.1111/j.1600-0781.2006.00222.x · doi:10.1111/j.1600-0781.2006.00222.x
  19. 10.1111/j.1468-3083.2006.01897.x · DOI · Paper page
  20. 10.1111/j.1365-2230.2009.03765.x · DOI · Paper page

Cited by

Metadata

Authors
Narayan, V. S., Uitentuis, S. E., Luiten, R. M., Bekkenk, M. W., & Wolkerstorfer, A.
Venue
Journal of the European Academy of Dermatology and Venereology
Publisher
Wiley
Published
2020-10-07
Volume
35
Issue
3
Pages
744-748
ISSN
  • 0926-9959 (ISSN-L)
  • 1468-3083
OpenAlex
W3083911803
Cited by
49
References
0
FWCI
2.48
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.